Ocugen (OCGN) Change in Accured Expenses (2014 - 2026)
Ocugen's (OCGN) quarterly Change in Accured Expenses came in at -$5.4 million in Q1 2026, down 65.18% YoY from -$15.5 million in Q1 2025, and down 547.6% on a QoQ basis from $1.2 million in Q4 2025.
Analysis
Ocugen (OCGN) Change in Accured Expenses (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Change in Accured Expenses data on file, last reported at -$5.4 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 65.18% year-over-year to -$5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 48.98% YoY) and the FY2025 annual result came in at $3.3 million, down 19.97% from the prior year.
- Change in Accured Expenses declined to -$5.4 million in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $3.9 million in Q3 2022 to a low of -$5.4 million in Q1 2026.
- A 5-year average of -$47411.8 and a median of $1.2 million in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 380.45% — and 2023, when it sank 3889.31%.
- Tracing OCGN's Change in Accured Expenses over 5 years: stood at $2.8 million in 2022, then slumped by 170.5% to -$1.9 million in 2023, then soared by 207.62% to $2.1 million in 2024, then slumped by 42.27% to $1.2 million in 2025, then plunged by 547.6% to -$5.4 million in 2026.
- The last three Change in Accured Expenses figures came in at -$5.4 million (Q1 2026), $1.2 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - | 5.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.04 Mn |
| Mar 31, 2026 | -5.40 Mn |
| Dec 31, 2025 | 1.21 Mn |
| Sep 30, 2025 | 3.29 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Dec 31, 2024 | 2.09 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 1.33 Mn |
| Mar 31, 2024 | -1.45 Mn |
| Dec 31, 2023 | -1.94 Mn |
| Sep 30, 2023 | -1.35 Mn |
| Jun 30, 2023 | -4.09 Mn |
| Mar 31, 2023 | -4.96 Mn |
| Dec 31, 2022 | 2.75 Mn |
| Sep 30, 2022 | 3.89 Mn |
| Jun 30, 2022 | 2.71 Mn |
| Mar 31, 2022 | 131,000.00 |
| Dec 31, 2021 | 573,000.00 |
| Sep 30, 2021 | 1.44 Mn |